Akebia Therapeutics: HC Wainwright Raises PT to $6, Keeps Buy Rating

Friday, Feb 6, 2026 7:33 am ET1min read
AKBA--

Akebia Therapeutics: HC Wainwright Raises PT to $6, Keeps Buy Rating

Akebia Therapeutics: HC Wainwright Raises PT to $6, Keeps Buy Rating

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet